Ascentage Pharma Group International
Ascentage Pharma Group International (ASPHF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
asphf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Ascentage Pharma Group International (ASPHF) measures how much investors pay for each dollar of the company's trailing earnings. ASPHF's current PE ratio of N/A is calculated by dividing its stock price of $4.53 by its TTM earnings per share of -$3.33.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2016 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Ascentage Pharma Group InternationalYou ASPHF | $1.7B | N/A | — | -$3.33 |
 Ascentage Pharma Group International AAPGV | $127M | N/A | — | -$5.37 |
 Abcam plc ABCZF | $5.1B | N/A | — | $0.00 |
 Mediclinic International plc ANHGY | $4.0B | N/A | — | — |
 Biotest AG BIESF | $1.6B | 41.48x | +24.1% | $0.71 |
 Galenica AG GALNF | $5.7B | 25.35x | -24.1% | $3.63 |
 Indivior PLC INVVY | $3.0B | N/A | — | -$0.38 |
Industry Average 2 peers with valid PE | — | 33.41x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.40 | — | |
2024-12-31 FY2024 | — | $-1.37 | — | |
2023-12-31 FY2023 | — | $-3.28 | — | |
2022-12-31 FY2022 | — | $-3.35 | — | |
2021-12-31 FY2021 | — | $-3.07 | — | |
2020-12-31 FY2020 | — | $-3.14 | — | |
2019-12-31 FY2019 | — | $-12.69 | — | |
2018-12-31 FY2018 | — | $-1.67 | — | |
2017-12-31 FY2017 | — | $-0.57 | — | |
2016-12-31 FY2016 | — | $-0.52 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Ascentage Pharma Group International (ASPHF) measures how much investors pay for each dollar of the company's trailing earnings. ASPHF's current PE ratio of N/A is calculated by dividing its stock price of $4.53 by its TTM earnings per share of -$3.33.
Frequently asked questions
ASPHF pe ratio · 6 questionsASPHF's current PE ratio is N/A as of 2026-06-08, based on a stock price of $4.53 and TTM EPS of -$3.33. Data sourced from Financial Modeling Prep via ASPHF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Ascentage Pharma Group International SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08